Daily Trades
- Dylan Jovine
I have a simple cash skim for you today: HashiCorp (SYM: HCP) here at $32.50.
- Dylan Jovine
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
- Dylan Jovine
The biotech sector has sold off big time in the past 60 days, and Iovance (SYM: IOVA) has sold off along with it.
- Dylan Jovine
Back in the 90’s, Wall Street started putting pressure on Big Pharma to get better returns on their R&D spending.
- Dylan Jovine
Judging by all the emails we got over the weekend, most of you know Iovance Biotheutics (SYM: IOVA) won FDA approval for lifileucel.
- Dylan Jovine
Rumors of a takeover have surrounded Shockwave for years. This cardiovascular device maker would make a great fit for Johnson & Johnson, Medtronic or Boston Scientific.
- Dylan Jovine
I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).
- Dylan Jovine
I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.
- Dylan Jovine
Iovance (SYM: IOVA) jumped 20% today after announcing news that its lung cancer candidate LN-145 could be acceptable for a potential accelerated approval.
- Dylan Jovine
We have a strong group of stocks, so I want to take today to highlight some of the best opportunities I haven’t talked about recently (and update others).
deal of the month
Categories
Dylan Jovine | A Memorial Day Tribute: The Real Meaning Behind Our Freedom
Dylan Jovine | Why the Market Crashed This Week | Yield Surge Explained & What Happens Next
Dylan Jovine | Trump’s $1 Trillion Space Defense Plan: SpaceX, RTX & Palantir Involved
Recent posts
Tags
Connect with Us
- Dylan Jovine
I have a simple cash skim for you today: HashiCorp (SYM: HCP) here at $32.50.
- Dylan Jovine
My dear mother has early-stage Alzheimer’s. What they say is true: it’s not pretty.
- Dylan Jovine
The biotech sector has sold off big time in the past 60 days, and Iovance (SYM: IOVA) has sold off along with it.
- Dylan Jovine
Back in the 90’s, Wall Street started putting pressure on Big Pharma to get better returns on their R&D spending.
- Dylan Jovine
Judging by all the emails we got over the weekend, most of you know Iovance Biotheutics (SYM: IOVA) won FDA approval for lifileucel.
- Dylan Jovine
Rumors of a takeover have surrounded Shockwave for years. This cardiovascular device maker would make a great fit for Johnson & Johnson, Medtronic or Boston Scientific.
- Dylan Jovine
I’m also thankful that I get to share some good news with you today regarding Iovance Biotherapeutics (SYM: IOVA).
- Dylan Jovine
I’ve been touting Iovance (SYM: IOVA) for so long, I may have to fall on my sword Japanese-style if it doesn’t work out.
- Dylan Jovine
Iovance (SYM: IOVA) jumped 20% today after announcing news that its lung cancer candidate LN-145 could be acceptable for a potential accelerated approval.
- Dylan Jovine
We have a strong group of stocks, so I want to take today to highlight some of the best opportunities I haven’t talked about recently (and update others).
Get FREE Daily Stock Tips
Join and receive market insider stock picks, trade alerts and unique investing insights
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.